Antihypertensive drugs, particularly those acting on the renin-angiotensin-aldosterone system, regress left ventricular hypertrophy, improving systolic performance and prognosis in hypertensive patients.
The detection, prevention, and reversal of LVH using antihypertensive therapy is a critical component of hypertension management to prevent heart failure and cardiovascular events.
At some point in the natural history of hypertension, the compensatory increase in left ventricular mass ceases to be beneficial. Left ventricular hypertrophy (LVH) becomes a preclinical disease and an independent risk factor for congestive heart failure, ischemic heart disease, arrhythmia, sudden death, and stroke. In addition to elevated BP, several mechanisms are involved, including body size, age, gender, race, fibrogenic cytokines, and neurohumoral factors, notably angiotensin II, which favor interstitial collagen deposition and perivascular fibrosis. These tissue changes are responsible for the insidious contractile dysfunction that is associated with LVH, consequent to decreased coronary reserve and altered diastolic ventricular filling and relaxation. The cardinal investigations are echocardiography and electrocardiography. All antihypertensive drugs regress LVH, notably those that act on the renin-angiotensin-aldosterone system, which also could target the detrimental tissue changes. Regression enhances systolic midwall performance, normalizes autonomic function, and restores coronary reserve. The resulting improvement in prognosis has enshrined the detection, prevention, and reversal of LVH in the current guidelines of hypertension management.
Agabiti‐Rosei et al. (Fri,) conducted a review in Hypertension with Left Ventricular Hypertrophy. Antihypertensive drugs (especially RAAS inhibitors) was evaluated. Antihypertensive drugs, particularly those acting on the renin-angiotensin-aldosterone system, regress left ventricular hypertrophy, improving systolic performance and prognosis in hypertensive patients.